Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Hindsight>Brokers' Latest TPs & Views on JD HEALTH Post-results
Recommend 13 Positive 16 Negative 1 |
||||
|
||||
|
JD HEALTH (06618.HK) announced its interim results after the market closed yesterday. The company's share price opened 3% higher this morning (14th) and once surged by 16.7% to an intraday high of HKD64. It last traded at HKD62.2, up 13.4%, with a turnover of HKD787 million, making it the best-performing blue-chip stock. Listed below are the latest investment ratings, target prices, and views of three brokers on JD HEALTH: Broker│Investment Rating│Target Price (HKD) HSBC Global Research│Hold -> Buy│49 -> 65 CLSA│Outperform│56 -> 64 Morgan Stanley│Equalweight│46 -> 52.5 Broker│View HSBC Global Research│2Q results beat as driven by advertising and pharma sales CLSA│Pharma sales grew strongly Morgan Stanley│Momentum in holdings additions persisted AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
